ELI LILLY AND COMPANY |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 749.5 USD | -0.16% |
|
-0.75% | +28.93% |
| 05:56am | Eli Lilly's $14 Million Insulin Settlement Shelved Amid Unfavorable Ruling | MT |
| Apr. 15 | More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm | RE |
Financials (USD)
| Sales 2024 * | 41.33B | Sales 2025 * | 51.21B | Capitalization | 676B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.93B | Net income 2025 * | 15.83B | EV / Sales 2024 * | 16.7 x |
| Net Debt 2024 * | 15.19B | Net Debt 2025 * | 10.74B | EV / Sales 2025 * | 13.4 x |
| P/E ratio 2024 * |
61.7
x | P/E ratio 2025 * |
41.8
x | Employees | 43,000 |
| Yield 2024 * |
0.69% | Yield 2025 * |
0.8% | Free-Float | 99.79% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +0.63% | ||
| 1 week | -3.41% | ||
| Current month | -3.50% | ||
| 1 month | -0.45% | ||
| 3 months | +16.78% | ||
| 6 months | +23.24% | ||
| Current year | +28.79% |
1 week
746.83
768.00
1 month
746.83793.67
Current year
579.05800.78
1 year
367.35800.78
3 years
178.58800.78
5 years
101.36800.78
10 years
57.35800.78
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 59 | 04-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 18 M€ | +3.25% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-16 | 751.5 | +0.09% | 1 682 493 |
| 24-04-15 | 750.8 | -0.12% | 2,358,569 |
| 24-04-12 | 751.6 | -1.05% | 2,495,037 |
| 24-04-11 | 759.6 | -0.31% | 1,594,834 |
| 24-04-10 | 762 | +0.63% | 1,700,296 |
Delayed Quote Nyse, April 15, 2024 at 04:00 pm EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
2024-04-30
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
750.8
USD
Average target price
812.9
USD
Spread / Average Target
+8.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +28.79% | 676B | |
| +23.64% | 559B | |
| -5.84% | 356B | |
| +15.75% | 320B | |
| +4.32% | 286B | |
| +3.28% | 213B | |
| -0.02% | 207B | |
| -9.04% | 199B | |
| -10.00% | 147B | |
| -7.82% | 142B |
- Stock Market
- Equities
- LLY Stock
